Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of breast carcinoma: Indications and pitfalls with illustrative case examples

Moheieldin M Abouzied; Ahmed Fathala; Ahmad AlMuhaideb; Mohammed H Al Qahtani

doi:10.4103/wjnm.WJNM_88_19

Role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of breast carcinoma: Indications and pitfalls with illustrative case examples

World J Nucl Med. 2020 Jul 1;19(3):187-196. doi: 10.4103/wjnm.WJNM_88_19. eCollection 2020 Jul-Sep.

Authors

Moheieldin M Abouzied¹, Ahmed Fathala¹, Ahmad AlMuhaideb¹, Mohammed H Al Qahtani²

Affiliations

¹ Department of Radiology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
² Department of Cyclotron and Radiopharmaceuticals, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Abstract

Whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography (PET) has been used extensively in the last decade for the primary staging and restaging and to assess response to therapy in these patients. We aim to discuss the diagnostic performance of PET/computed tomography in the initial staging of breast carcinoma including the locally advanced disease and to illustrate its role in restaging the disease and in the assessment of response to therapy, particularly after the neoadjuvant chemotherapy. Causes of common pitfalls during image interpretations will be also discussed.

Keywords: 18F-fluorodeoxyglucose; breast carcinoma; positron emission tomography/computed tomography.

Publication types

Review